ArticleInternational journal of molecular sciences2025
Early Immune Cell and Antibody Kinetics Following SARS-CoV-2 Vaccination in Healthy Adults and Low-Count Monoclonal B-Cell Lymphocytosis.
Guillermo Oliva-Ariza, Ignacio Criado, Blanca Fuentes-Herrero, Cristina Carbonell, José Ignacio Sánchez-Gallego, Amparo López-Bernús, María Laura Gutiérrez, Alejandro Rolo-Ramírez, Marta Bernal-Ribes, Yolimar Almenara-Morales and 6 more
Abstract read
In one paragraphArticle in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Guillermo Oliva-ArizaTranslational and Clinical Research Program, Cancer Research Center (IBMCC, Instituto de Biología Molecular y Celular del Cáncer, CSIC-University of Salamanca), Cytometry Service, NUCLEUS, 37007 Salamanca, Spain.ORCID 0000-0002-9653-9849 Ignacio CriadoTranslational and Clinical Research Program, Cancer Research Center (IBMCC, Instituto de Biología Molecular y Celular del Cáncer, CSIC-University of Salamanca), Cytometry Service, NUCLEUS, 37007 Salamanca, Spain.
Blanca Fuentes-HerreroTranslational and Clinical Research Program, Cancer Research Center (IBMCC, Instituto de Biología Molecular y Celular del Cáncer, CSIC-University of Salamanca), Cytometry Service, NUCLEUS, 37007 Salamanca, Spain.
Cristina CarbonellDepartment of Medicine, University of Salamanca, 37007 Salamanca, Spain.
José Ignacio Sánchez-GallegoTranslational and Clinical Research Program, Cancer Research Center (IBMCC, Instituto de Biología Molecular y Celular del Cáncer, CSIC-University of Salamanca), Cytometry Service, NUCLEUS, 37007 Salamanca, Spain.
María Laura GutiérrezTranslational and Clinical Research Program, Cancer Research Center (IBMCC, Instituto de Biología Molecular y Celular del Cáncer, CSIC-University of Salamanca), Cytometry Service, NUCLEUS, 37007 Salamanca, Spain.ORCID 0000-0003-2997-6317 Alejandro Rolo-RamírezDepartment of Internal Medicine, University Hospital of Salamanca, 37007 Salamanca, Spain.ORCID 0000-0001-6240-7218 Marta Bernal-RibesTranslational and Clinical Research Program, Cancer Research Center (IBMCC, Instituto de Biología Molecular y Celular del Cáncer, CSIC-University of Salamanca), Cytometry Service, NUCLEUS, 37007 Salamanca, Spain.
Yolimar Almenara-MoralesDepartment of Internal Medicine, University Hospital of Salamanca, 37007 Salamanca, Spain.
Quentin LecrevisseTranslational and Clinical Research Program, Cancer Research Center (IBMCC, Instituto de Biología Molecular y Celular del Cáncer, CSIC-University of Salamanca), Cytometry Service, NUCLEUS, 37007 Salamanca, Spain.ORCID 0000-0001-8715-5846 Jacques J M van DongenTranslational and Clinical Research Program, Cancer Research Center (IBMCC, Instituto de Biología Molecular y Celular del Cáncer, CSIC-University of Salamanca), Cytometry Service, NUCLEUS, 37007 Salamanca, Spain.ORCID 0000-0002-3650-7087 Julia AlmeidaTranslational and Clinical Research Program, Cancer Research Center (IBMCC, Instituto de Biología Molecular y Celular del Cáncer, CSIC-University of Salamanca), Cytometry Service, NUCLEUS, 37007 Salamanca, Spain.ORCID 0000-0003-3124-8917 Alberto OrfaoTranslational and Clinical Research Program, Cancer Research Center (IBMCC, Instituto de Biología Molecular y Celular del Cáncer, CSIC-University of Salamanca), Cytometry Service, NUCLEUS, 37007 Salamanca, Spain.ORCID 0000-0002-0007-7230 ECRIN-M3 Consortium
Funding
Consejería de Educación de la Junta de Castilla y León PR-2019 487971Consejería de Educación de la Junta de Castilla y León SA109P20Consejería de Educación de la Junta de Castilla y León SA207P23Instituto de Salud Carlos III CB16/12/00400Instituto de Salud Carlos III COV20/00386Instituto de Salud Carlos III PI17/00399Instituto de Salud Carlos III PI22/00674Ministerio de Ciencia, Innovación y Universidades JC2020-044160-I
6 · The paper itselfAbstract
The early immune kinetics after SARS-CoV-2 vaccination remain poorly understood, particularly among individuals with low-count monoclonal B-cell lymphocytosis (MBL
Indexed as
Antibodies, ViralB-LymphocytesCOVID-19COVID-19 VaccinesLymphocytosisSARS-CoV-2AdultFemaleHumansKineticsMaleMiddle AgedPlasma CellsVaccinationAntibodies, ViralCOVID-19 VaccinesCOVID-19Immune responseimmunodeficiencylow-count monoclonal B-cell lymphocytosisSARS-CoV-2vaccination
Identifiers
PMID39859394
PMCPMC11765611
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390